Sign In
Buy TEM
$50.56
-1.76 (-3.36%)
At Close: Jun 16, 2026
Tempus AI Expands Clinical Validation of AI-Powered Cancer Diagnostics
11:20am, Thursday, 12'th Mar 2026
TEM advances precision oncology as studies validate IPS, PurIST and xF+ diagnostics, highlighting stronger guidance for cancer therapy and biomarker detection.
Why Tempus AI Stock Is Up Wednesday?
10:39am, Wednesday, 11'th Mar 2026
Tempus AI Inc (NASDAQ: TEM) shares are trading higher Wednesday morning after Needham analyst Ryan MacDonald reiterated a Buy rating on the stock and maintained a $75 price target.
Tempus Announces Study Highlighting the Role of Advanced Genomic Profiling Features in Identifying Clinically Actionable Findings
08:30am, Wednesday, 11'th Mar 2026
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the publication of a new study in JCO Precision
Should You Buy, Hold or Sell Tempus AI Stock Heading Into 2026?
10:01am, Monday, 09'th Mar 2026
TEM eyes 2026 growth by scaling diagnostics, MRD testing and AI-driven clinical apps as revenues surge 83%, though valuation concerns temper the outlook.
TEM's Diagnostics Arm Expanding Rapidly: What's Driving the Growth?
09:46am, Thursday, 05'th Mar 2026
Tempus AI's diagnostics arm is surging in 2025 as precision oncology testing, MRD adoption, AI-driven genomic tools and the Ambry Genetics acquisition expand capabilities.
Tempus AI, Inc. (TEM) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript
03:12pm, Tuesday, 03'rd Mar 2026
Tempus AI, Inc. (TEM) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript
AI-Powered Tempus Inks New Multi-Year Merck Deal
02:33pm, Tuesday, 03'rd Mar 2026
Tempus AI Inc. (NASDAQ: TEM) on Tuesday inked a strategic collaboration agreement with Merck & Co. Inc. (NYSE: MRK) aimed at accelerating AI-driven precision medicine.
Hospital Networks Turn to AI-Enhanced Cardiac Imaging to Cut Costs and Improve Outcomes
12:19pm, Tuesday, 03'rd Mar 2026
/PRNewswire/ -- USANewsGroup.com News Commentary - AI is making its way through the halls of our entire medical system, and the implementation is accelerating
Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine
08:30am, Tuesday, 03'rd Mar 2026
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Merck, known as MSD outside of the United States and Canada,
After a Near 50% Drop, Tempus AI Could Be Ripe for a Rebound
07:24pm, Friday, 27'th Feb 2026
Since going public in mid-2024, shares of healthcare and life science services company Tempus AI NASDAQ: TEM have gone on a wild rollercoaster ride. The firm's initial public offering price was $37.
Dakota Wealth Management Has $1.06 Million Stock Holdings in Tempus AI, Inc. $TEM
04:54am, Friday, 27'th Feb 2026
Dakota Wealth Management lessened its position in Tempus AI, Inc. (NASDAQ: TEM) by 75.8% in the undefined quarter, according to the company in its most recent filing with the SEC. The institutional in
TEM vs. ILMN: Which MedTech Stock Offers Greater Upside?
11:51am, Thursday, 26'th Feb 2026
In 2026, MedTech players' success will hinge on their ability to balance near-term pressure with long-term transformation. Per a report by ZS, these players must address immediate operational, financi
Tempus AI: Buy The Post-Earnings Dip
10:16am, Thursday, 26'th Feb 2026
Tempus AI maintains strong Q4 momentum, with robust testing stats and improving financials despite recent post-earnings stock weakness. Oncology testing volume grew 29% YoY, and net revenue retention
Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference
08:30am, Thursday, 26'th Feb 2026
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Morgan Stanley T
Cathie Wood Is Buying The Tempus AI Dip, Ark Snaps Up Stock Worth $11 Million
09:20pm, Wednesday, 25'th Feb 2026
On Wednesday, Feb. 25, 2026, Cathie Wood-led Ark Invest bought $11M in Tempus AI after a 7% drop
